论文部分内容阅读
目的分析亚胺培南/西司他丁治疗儿童异基因造血干细胞移植(Allo-HSCT)早期合并感染的疗效。方法本院儿科2008年10月-2010年7月共收治Allo-HSCT患儿75例。其中男55例,女20例;年龄0.8～15.0岁。对75例儿童Allo-HSCT治疗过程中感染发生部位及时间、临床标本病原菌分布及亚胺培南/西司他丁治疗后的转归情况进行分析,治疗效果根据卫生部新药临床研究指导原则标准进行评定。结果感染发生于Allo-HSCT后0～10 d。75例患儿经抗感染及支持治疗,痊愈52例(69.3%);显效+进步9例(12.0%);总有效61例(81.3%)。结论应用亚胺培南/西司他丁治疗儿童Allo-HSCT合并早期感染,疗效可靠,具有疗效快、作用显著的特点。
Objective To analyze the efficacy of imipenem / cilastatin in the treatment of early combined infection in children with allogeneic hematopoietic stem cell transplantation (Allo-HSCT). Methods A total of 75 children with Allo-HSCT were treated in our hospital from October 2008 to July 2010. Including 55 males and 20 females; aged 0.8 to 15.0 years. 75 cases of children with Allo-HSCT infection occurred during the treatment of parts and time, the distribution of clinical specimens of pathogens and imipenem / cilastatin after the treatment of the prognosis were analyzed according to the Ministry of Health clinical trial guidelines To assess. Results The infection occurred 0-10 days after Allo-HSCT. In 75 cases, 52 cases (69.3%) were cured by anti-infective and supportive therapy, 9 cases (12.0%) were markedly effective and advanced, and 61 cases (81.3%) were effective. Conclusion The application of imipenem / cilastatin in treatment of childhood Allo-HSCT combined with early infection has reliable curative effect and quick curative effect and significant effect.